New OrbiMed-backed biotech aims to replicate Vertex's wildly successful cystic fibrosis pills in other diseases

A new biotech aiming to tackle protein misfolding has landed a substantial Series A from some blue-chip investors.

Congruence Therapeutics burst onto the scene Tuesday with a $50 million round, including funds from OrbiMed. The biotech will use the money to advance its platform and move some of its programs forward, CEO Clarissa Desjardins told Endpoints News.